Correspondence 0001193125-24-250670 from CATALYST PHARMACEUTICALS, INC. (CPRX) (CIK 0001369568) (CPRX)
CATALYST PHARMACEUTICALS, INC. (CPRX) (CIK 0001369568)
Date: Nov. 4, 2024 · CIK: 0001369568 · Accession: 0001193125-24-250670
AI Filing Summary & Sentiment
File numbers found in text: 001-33057
Referenced dates: August 16, 2024, September 17, 2024
Letter
November 4, 2024
VIA EDGAR Submission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Sasha Parikh
Jenn Do
Re: Catalyst Pharmaceuticals, Inc.
Form 10-Q for the period ending June 30, 2024
Filed August 7, 2024
Form 8-K filed February 29, 2024
File No. 001-33057
Ladies and Gentlemen:
Catalyst Pharmaceuticals, Inc. (the “Company”) is submitting this letter in response to the Staff’s comment letter, dated September 17, 2024, which comment letter follows up on the Staff’s comment letter to the Company dated August 16, 2024, the Company’s response to such comment letter, dated September 5, 2024, and the subsequent phone conversations between the undersigned, the Company’s securities counsel, and members of the Staff of the U.S. Securities and Exchange Commission (“Commission”) with respect to the Company’s Form 8-K filed on February 29, 2024. For your convenience, we have recited the Staff’s comment in boldface type and provided our response to such comment immediately thereafter.
Form 8-K filed February 29, 2024
Exhibit 99.1
Reconciliation of Non-GAAP Metrics, page 9
1. We have reviewed your response to prior comment 1. We believe adjustments to exclude acquired in-process research and development expense are inconsistent with the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations. Please confirm to us that you will no longer include these adjustments in any non-GAAP financial measure presented in accordance with Item 10(e) of Regulation S-K or Regulation G as well as the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.
As discussed with the Staff, the Company confirms that it will no longer include acquisition in-process research and development expense in Non-GAAP financial measures reported in its future SEC filings. Further prior period comparatives in such filings will be conformed to the current period presentation.
* * * * *
355 Alhambra Circle, Suite 801 | Coral Gables, FL 33134 | Phone (305) 420-3200 | Fax (305) 569-0233
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
November 4, 2024
Page 2
The Company acknowledges that it and its management are responsible for the accuracy and adequacy of its disclosures, notwithstanding any review, comments, action, or absence of action by the staff.
Thank you for your continued assistance with this filing. If you have any questions, please call me at (305) 420-3200 or our counsel, Philip Schwartz at Akerman LLP at (954) 468-2455.
Sincerely,
CATALYST PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP November 4, 2024 VIA EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Sasha Parikh Jenn Do Re: Catalyst Pharmaceuticals, Inc. Form 10-Q for the period ending June 30, 2024 Filed August 7, 2024 Form 8-K filed February 29, 2024 File No. 001-33057 Ladies and Gentlemen: Catalyst Pharmaceuticals, Inc. (the “Company”) is submitting this letter in response to the Staff’s comment letter, dated September 17, 2024, which comment letter follows up on the Staff’s comment letter to the Company dated August 16, 2024, the Company’s response to such comment letter, dated September 5, 2024, and the subsequent phone conversations between the undersigned, the Company’s securities counsel, and members of the Staff of the U.S. Securities and Exchange Commission (“Commission”) with respect to the Company’s Form 8-K filed on February 29, 2024. For your convenience, we have recited the Staff’s comment in boldface type and provided our response to such comment immediately thereafter. Form 8-K filed February 29, 2024 Exhibit 99.1 Reconciliation of Non-GAAP Metrics, page 9 1. We have reviewed your response to prior comment 1. We believe adjustments to exclude acquired in-process research and development expense are inconsistent with the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations. Please confirm to us that you will no longer include these adjustments in any non-GAAP financial measure presented in accordance with Item 10(e) of Regulation S-K or Regulation G as well as the guidance in Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations. As discussed with the Staff, the Company confirms that it will no longer include acquisition in-process research and development expense in Non-GAAP financial measures reported in its future SEC filings. Further prior period comparatives in such filings will be conformed to the current period presentation. * * * * * 355 Alhambra Circle, Suite 801 | Coral Gables, FL 33134 | Phone (305) 420-3200 | Fax (305) 569-0233 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences November 4, 2024 Page 2 The Company acknowledges that it and its management are responsible for the accuracy and adequacy of its disclosures, notwithstanding any review, comments, action, or absence of action by the staff. Thank you for your continued assistance with this filing. If you have any questions, please call me at (305) 420-3200 or our counsel, Philip Schwartz at Akerman LLP at (954) 468-2455. Sincerely, CATALYST PHARMACEUTICALS, INC. /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer cc: Richard J. Daly President and Chief Executive Officer Catalyst Pharmaceuticals, Inc. Philip B. Schwartz, Esq. Akerman LLP